Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Risk factors

Hyperhomocysteinemia: a renal and cardiovascular risk factor?

Nature Reviews Nephrology volume 6, pages 695–696 (2010)Cite this article

Subjects

One recent trial failed to show any beneficial effect of homocysteine lowering using vitamin B therapy on survival and cardiovascular events in patients with end-stage renal disease, and results of another study in patients with early-stage diabetic nephropathy actually suggested that vitamin B therapy has harmful effects. Do these findings mark the end of the era of studies investigating homocysteine lowering in patients with chronic kidney disease?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Consequences of folic acid treatment.

References

  1. McCully, K. S. Hyperhomocysteinemia and arteriosclerosis: historical perspectives. Clin. Chem. Lab. Med. 43, 980–986 (2005).

    Article  CAS  Google Scholar 

  2. Heinz, J. et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 121, 1432–1438 (2010).

    Article  CAS  Google Scholar 

  3. House, A. A. et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303, 1603–1609 (2010).

    Article  CAS  Google Scholar 

  4. Kluijtmans, L. A. et al. The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am. J. Hum. Genet. 65, 59–67 (1999).

    Article  CAS  Google Scholar 

  5. Wald, D. S., Law, M. & Morris, J. K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202 (2002).

    Article  Google Scholar 

  6. Wald, D. S., Wald, N. J., Morris, J. K. & Law, M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 333, 1114–1117 (2006).

    Article  CAS  Google Scholar 

  7. Zoungas, S. et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J. Am. Coll. Cardiol. 47, 1108–1116 (2006).

    Article  CAS  Google Scholar 

  8. Bønaa, K. H. et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 354, 1578–1588 (2006).

    Article  Google Scholar 

  9. de Jager, D. J. et al. Cardiovascular and non-cardiovascular mortality among patients initiating dialysis. JAMA 302, 1782–1789 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrology, Hypertension & Renal Transplantation Unit and CNR-IBIM Clinical Epidemiology of Renal Diseases and Hypertension, Ospedali Riuniti, Reggio Calabria, Italy

    Carmine Zoccali

  2. Department of Medical Informatics, ERA-EDTA Registry, Academic Medical Center, Amsterdam, The Netherlands

    Kitty J. Jager

Authors
  1. Carmine Zoccali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kitty J. Jager
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmine Zoccali.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zoccali, C., Jager, K. Hyperhomocysteinemia: a renal and cardiovascular risk factor?. Nat Rev Nephrol 6, 695–696 (2010). https://doi.org/10.1038/nrneph.2010.142

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2010.142

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing